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Short-term cellular effects induced by castration
therapy in relation to clinical outcome in prostate
cancer
P Stattin1, P Westin2, J-E Damber1 and A Bergh2
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Summary To explore the relationship between short-term effects of castration therapy and clinical response, biopsies obtained before and a
week after castration therapy from 15 responding and 13 non-responding patients with prostate cancer were investigated. The biopsies were
assessed for regressive morphology, apoptotic index by morphological criteria, nuclear area, and immunoreactivity (IR) for Ki-67, p53, bcl-2,
bax and Fas. The index was defined as the percentage of immunoreactive cells in a tumour. Regressive morphology was observed in 14 out
of 15 responding tumours aftertherapy, compared with 4 out of 13 non-responders (P< 0.001). Median tumourepithelial cell nuclear area and
Ki-67 index decreased equally in both groups. The median apoptotic index increased from 2.6 to 3.5 after castration among responders
(P < 0.05), whereas it remained at 2.8 among non-responders. p53 IR was present in three tumours before castration; after therapy p53
reactivity was seen in three additional tumours belonging to the responding group. Median bcl-2 index increased in responders from 1.5 to
10.0 (P < 0.05), and in non-responders from 0.08 to 2.7 (P < 0.05). Bax IR and Fas IR were present in all tumours before therapy and
unchanged after therapy. Thus, regressive morphology and an increase in apoptotic index were related to a favourable clinical response.
These data suggest that it might be possible to predict the effect of castration therapy by examining tumour biopsies shortly after treatment.
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Castration therapy remains first-line treatment of advanced prostate
cancer, although only 80% ofthepatients willhave afavourable clin-
icalresponse (Resnick etal, 1975). Atpresent, thebestway topredict
clinical response is to measure the serum level of prostate-specific
antigen (PSA) 3-6 months after castration. A normalization of the
PSA value at that time, predicts along relapse-free survival, whereas
an elevated PSA predicts a poor response (Petros et al, 1993; Fowler
et al, 1995). Consequently, the nadir PSA can be used as a surrogate
end-point (Bostwick et al, 1994). Prediction ofresponse at an earlier
time, forexample atthetimeofinitiation ofcastration therapy, would
allow for up-front treatment of non-responding, androgen-indepen-
dent tumours with potent adjuvant drugs that will, it is hoped, be
available in the future. Little is known about the short-term cellular
effects induced by androgen deprivation in human prostate tumours,
and the prognostic implications these effects may have. It has long
been assumed that human prostate cancers react in a fashion similar
to the normal prostate inrodents. In the rat ventral prostate, androgen
depletion induces massive apoptosis and involution of the organ
(Kyprianou et al, 1988). However, in an earlier study we found that
only approximately one-third of the tumours from prostate cancer
patients responded with an increase in apoptotic index 1 week after
castration, and that this response was unrelated to the effects on
proliferation (Westin et al, 1995a). The aim of this study was to
investigate whether the short-term effects of castration therapy on
morphology, apoptosis, proliferation and apoptosis-related oncogene
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expression in patients with prostate cancer are differential according
to subsequent clinical response.
MATERIAL AND METHODS
Patients
At least three ultrasound-guided core biopsies were obtained using
a spring-loaded 18 G BioptyCut gun shortly before and approxi-
mately a week after castration therapy in a series of patients with
advanced prostate cancer. This procedure was approved by the
local ethics commiitee, and the patients received information about
the study and gave their consent. Local tumour stage was evaluated
by rectal digital examination according to the UICC classification
(1992). Metastatic status was evaluated by radionuclide bone scan
at the time of diagnosis. To investigate the short-term effects in
tumours from patients with distinctly different outcome, two
groups of patients were selected. Response to castration therapy
was defined as a serum level of PSA of < 5 ng ml-' 3 months after
treatment, and non-response as a nadir PSA 2 10 ng ml-'. Using
these definitions, 15 responding patients were selected; 2 out of 15
(13%) died ofprostate cancer during the study period (mean obser-
vation time 19 months). A total of 13 non-responding patients were
identified; 8 out of 13 (62%) died of prostate cancer during the
study period. Mean cause-specific survival for PSA-responders
was 37 months, and for the non-responders 19 months (P = 0.004);
for patient characteristics see Table 1.
Tumour tissue processing and evaluation
Core biopsies were fixed in Bouin's solution, embedded in
paraffin, and cut in 4-gm-thick sections. Sections were stained
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Table 1 Clinical characteristics of patients prostate cancer treated with
castration therapy
Responders Non-responders
(n = 15)a (n = 13)
Tumour stageb
T1-T2 6 1
T3-T4 9 12
Tumour gradec
Gl, well differentiated 4 2
G2, intermediately 7 4
G3, poorly 4 7
Metastasis on bone scan 10 10
Patients aged at diagnosis (years) 79 (74-84) 76 (73-85)
PSA before therapy 43 (16-123) 396 (133-1635)
PSA nadir 2 (1-4) 76 (45-110)
Days between therapy and 7 (6-8) 6 (4-7.5)
post-therapy biopsy
Number of patients dead 2 8
because of disease
aResponse defined as PSA 5 < ng ml-1 3 months after castration therapy,
non-response defined as PSA 2 10 ng ml-1 at 3 months aftertherapy. bLocal
tumour stage according to UICC 1992. cTumour grade according to WHO
(Mostofi et al, 1980). dMedian values and 25% and 75% percentile values.
with haematoxylin and eosin. The tumour grade was evaluated
according to the WHO classification system as: well, intermedi-
ately or poorly differentiated (Mostofi et al, 1980) (Table 1). All
samples were analysed in a blind procedure by one observer
without previous knowledge ofthe patients.
Evaluation morphological response
The morphological response in the biopsies obtained after castra-
tion therapy was evaluated in terms of collapsed glandular acini
and cytoplasmatic vacuolization (Dhom et al, 1982). The response
was evaluated as all or none.
Determination of apoptotic index
The apoptotic index (percentage of apoptotic cells) was deter-
mined by evaluating 2500 tumour cells perpatient at 400 x magni-
fication before and after castration therapy. Apoptotic cells were
defined as single rounded cells or fragments with densely aggre-
gated chromatin and condensed cytoplasm, often lying in 'halos'
ofextracellular space (Kerr et al, 1972). Ifmore than one apoptotic
body were seen per 'halo', these were considered to originate from
the same cell and counted as one.
Nuclear area
The nuclear area of 150 randomly selected tumour cells was
measured and calculated using a MOP-Videoplan image analyser
(Landstrom et al, 1990) (Kontron AG, Germany).
Immunohistochemistry
Sections adjacent to the haematoxylin and eosin-stained sections
were deparaffinized, rehydrated, incubated in 0.3% hydrogen
peroxide in methanol, heated in a microwave oven for 5 x 4 min in
A
Figure 1 Microphotograph of a prostate tumour before (A), and 7 days after
(B) castration therapy, haematoxylin-eosin staining, 400 x magnification.
Induction of cytoplasmatic vacuolization (open arrow) and glandular collapse
(filled arrow) is apparent in the post-castration biopsy
0.01 M citrate buffer, pH 6, and incubated overnight with the
following antibodies: anti-p53 (2 mg/1-1, Ab 6, clone DO-1;
Oncogene Science, Cambridge, MA, USA), anti-bax (2 mg/l1-, bax
P-19; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Fas
(1 mg 1-', Fas N-18; Santa Cruz Biotechnology), anti-Ki-67
(2 mg 1-1, MIB-1; Immunotech, Marseille, France) respectively.
Sections were then incubated with a biotinylated secondary anti-
body, avidin-biotin complex reagents and peroxidase substrate for
development. Between incubations, the sections were washed with
phosphate-buffered saline. Bcl-2 immunoreactivity was obtained
using the anti-bcl-2 antibody (0.67 mg 1-1, clone 124; Cambridge
Biotechnology, Cambridge, MA, USA), and the supersensitive
multilink kit (BioGenex, San Ramon, CA, USA), alkaline
phosphatase and developed with fast red substrate.
Indexes (percentage of immunoreactive cells) for the apoptotic
related oncoproteins p53 and bcl-2, and for the proliferation asso-
ciated Ki-67 antigen (MIB-1) were determined by assessing the
presence of immunoreactivity in at least 1000 randomly selected
tumour cells at 400 x magnification with the aid of an eye-piece
graticule in at least two slides from each tumour before and after
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Table 2 Short-term effects after castration therapy in patients with advanced prostate cancer
Respondersa Non-respondersb
Before After Before After
Proliferation index (%)c 2.8 (1.3-5.1) 1.1 (0.5-2)* 5.3 (1.9-8.4) 0.5 (0.1-2.6)*
Apoptotic index (%)d 2.6 (1.0-3.7) 3.5 (1.8-4.8)" 2.8 (1.9-3.4) 2.8 (1.9-3.8)
bcl-2 index (%) 1.5 (0.4-8.5) 10.0 (2.2-5.3) 0.1 (0-3.8) 2.7 (0.2-8.8)"
Nuclear area (m2)e 24 (23-25) 18 (17-21)* 23 (22-25) 19 (17-20)*
Median values (25 and 75% percentiles). aResponse defined as PSA 5 < ng ml-' 3 months after castration therapy, non-response. bNon-response defined as
PSA 2 10 ng ml-1 at 3 months after therapy. cProliferation measured by Ki-67 immunoreactivity with the MAb MIB-1. dApoptotic signs evaluated on H and
E-stained slides in 2500 cells. eMean nuclear area calculated in 150 tumour cells morphometrically. *Difference before and aftertherapy (P= 0.0534).
"Significant difference (P< 0.05) between before and after therapy.
Table 3 Tumour response to castration therapy according to tumour grade
Tumour gradec Number of tumours Number of tumours with
Regressive Increased apoptotic
morphologya (%) indexb (%)
Gl Well differentiated 6 4 (66) 4 (66)
G2 Intermediately 11 8 (73) 9 (82)
G3 Poor 11 6 (55) 6 (55)
aRegressive morphology defined as collapsed glandular acini and cytoplasmic vacuolization (Dhom et al, 1982). bApoptotic signs evaluated on H and E-stained
slides in 2500 cells. cTumour grade according to WHO (Mostofi et al, 1980). No significant trend for either regressive morphology or increased apoptotic index
according to tumour grade by linear association test.
castration therapy. Immunoreactivity for bax and Fas was evalu-
ated by subjectively estimating the number ofreactive cells before
and after therapy.
Statistics
Non-parametric tests were applied to the results ofthe morpholog-
ical and immunohistochemical investigations as these results did
not appear to be normally distributed and the number of tumours
was small. Difference for paired variables was tested by the
Wilcoxon matched-pairs signed-ranks test, and with the
Mann-Whitney U-test for unrelated samples. Fisher's exact test
for independent samples was used for ordinal data. To test correla-
tions between unrelated variables, the Spearman rank-sum test
was applied. The median value was used for central tendency,
and the 25% and 75% percentile limits were used as a measure of
variability if not stated otherwise. Kaplan-Meier analysis was
performed for survival, and the log-rank test was used to test the
equality of the survival curves. In all tests, a two-tailed test of
significance was applied, and a P-value less than 0.05 was consid-
ered significant (Norusis 1993).
RESULTS
Morphology
Castration induced morphological regressive changes in 18 out of
28 (64%) ofthe post-treatment biopsies (Figure 1). The magnitude
of these changes varied among different tumours. In the group of
responders, 14 out of 15 (93%) of the tumours showed regressive
changes, compared with 4 out of 13 (31%) among the non-respon-
ders (P < 0.001). There was no significant correlation between the
induction ofmorphological changes and tumour grade.
Median nuclear area and cell proliferation rate
(Ki-67 index)
The median tumour nuclear area was 23 jim2 in the responding
tumours, and 24 jim2 in the non-responding group before therapy.
After castration therapy, the median nuclear area decreased signifi-
cantly to 18 jim2 among responders, and to 19 jim2 among non-
responders, i.e. virtually the same decrease in the two groups.
There was a wide range in the response inproliferation as measured
by Ki-67 immunoreactivity. In a few tumours, Ki-67 index actually
increased after therapy; however, the median Ki-67 index
decreased in both groups. In the responding group, median Ki-67
index decreased from 2.8 to 1.1 (P = 0.05), whereas it decreased
from 5.3 to 0.5 (P = 0.04) in the non-responding group (Table 2).
Apoptotic index
The apoptotic index before and aftertherapy as well as the change in
apoptotic rate was heterogeneous in both groups. The apoptotic
index increased in 12 out of 15 (80%) of the responding tumours,
and in 7 out of 13 (54%) of the non-responding tumours. In the
responding groups, the median apoptotic index increased from 2.6
before to 3.5 aftertherapy (P = 0.03), whereas inthenon-responding
group, the median apoptotic index was unchanged at 2.8 before and
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aftercastration (Table 2). The median apoptotic index in thebiopsies
from patients that died of prostate cancer decreased non-signifi-
cantly from 3.0 to 2.4, whereas it increased from 2.3 to 3.1
(P = 0.008) in the 18 patients that did not succumb to the disease
during the observation period. The indexes for apoptosis and pro-
liferation measured before therapy correlated weakly witheach other
(rs = 0.48, P = 0.009). Conversely, there were no significant correla-
tions between the changes in apoptotic index and histological grade
or morphological response. The distribution oftumours with regres-
sive morphology and increased apoptotic index according to tumour
grade is demonstrated in Table 3.
Immunohistochemical detection of p53, bcl-2, bax,
and Fas
p53 immunoreactivity was present at low frequency in three
tumours before castration therapy. The apoptotic index did not
increase in these tumours. After therapy, three additional tumours
were immunoreactive at a frequency of less than 5%, and these
three tumours all belonged to the responding group. All p53-posi-
tive tumours were also positive for bcl-2, but no correlation
between p53 and tumour differentiation, regressive morphology,
nuclear area or Ki-67 index was seen.
Bcl-2 immunoreactivity was heterogeneous, parts of the
tumours stained intensely whereas other parts did not stain at all.
Bcl-2 index was low in most tumours, 21 out of28 (75%) tumours
had an index below 5% before castration. After castration therapy
bcl-2 index increased in 19 out of 28 (68%) tumours, although it
remained below 5% in 12 out of 28 (43%) tumours. Median bcl-2
index in the responding group increased from 1.5 to 10 after
therapy (P = 0.002, Table 2). In the non-responding tumours
median bcl-2 index increased from 0.08 to 2.7 (P = 0.05). There
was a significant difference between responders and non-respon-
ders in the median bcl-2 index before therapy but not aftertherapy.
There was no correlation between bcl-2 indexes and grade,
morphological response or apoptotic index.
Bax immunoreactivity was present in the cytoplasm of virtually
all epithelial and stromal cells in the tumours before and after
therapy. In the benign epithelium, reactivity was most intense in the
luminal cells. No increase in the number of reactive cells or inten-
sity ofbax immunoreactivity could be seen after castration therapy.
Norelation tohistological grade, morphological response, apoptotic
index or immunoreactivity for Ki-67, p53, bcl-2 orFas was seen.
Fas immunoreactivity was also cytoplasmic and present in all
tumours. Most epithelial tumour cells were stained, but stromal
cells were negative. The number of reactive cells and intensity
varied slightly between tumours. However, castration therapy did
not affect the immunoreactivity for Fas. No correlation was found
to grade, morphological response and apoptotic index. No
immunoreactivity for Ki-67, p53, bcl-2 or bax was seen.
DISCUSSION
Regressive morphology
Tumour glandular and cellular morphology evaluated by light
microscopy may be regarded as a measure ofthe sum ofall genetic
and epigenetic events in the cell, and tumour differentiation has
repeatedly been shown to be a valid predictor for outcome in
prostate tumour (Vesalainen et al, 1994). Most cellular effects of a
change in the hormonal milieu in the normal prostate occur within
days after the change (Kyprianou et al, 1988). However, little is
known about the prognostic implications of the short-term
morphological response to androgen deprivation in human
prostate tumours. Collapse of glandular architecture and
vacuolization of the cytoplasm were apparent in 64% of the
tumours 1 week after androgen deprivation. Interestingly, a 68%
long-term (6 months or more) morphological response rate was
seen in tumours in patients treated with oestradiol (Dhom et al,
1982). The induction of regressive morphology was differential
according to PSA response, indicating that the extent of early
castration-induced cellular atrophy is related to PSA response and
probably also to long-term outcome.
Proliferation
Proliferation and cellular activity measured by nuclear area signi-
ficantly decreased in almost all tumours, and similarly, a 90%
decrease was observed in the mean serum PSA measured 3 months
after therapy in both responders and non-responders. However,
proliferation seemed dissociated from the tumour-suppressing
effects leading to clinical response as the decrease was almost
identical in the two groups. The reason for this somewhat
surprising observation is unknown.
Apoptosis
Human prostate tumours react with a decrease, no change or an
increase in the apoptotic rate after androgen deprivation (Westin et
al, 1995a). In this study, the median apoptotic index increased
significantly after androgen deprivation in the group of PSA-
responding tumours, whereas the median apoptotic index was
unaffected in the non-responding group. To the best ofour knowl-
edge, this is the first study to show that the apoptotic response
induced by castration in human prostate tumours is differential
according to subsequent clinical outcome.
Together with our earlier results (Westin et al, 1995a), these
data may reconcile contradictory data from experimental models;
for instance, castration induced an increase in apoptotic rate, a
decrease in proliferation rate and caused severe morphological
destruction in PC-82 human prostate cancer grown in nude mice
(Kyprianou et al, 1990; van Werden et al, 1993). Implants of the
newly established LuCaP 23.1 tumour cell line grown in nude
mice also underwent an increase in apoptosis and a decrease in
proliferation after castration (Bladou et al, 1996). In contrast,
androgen deprivation caused a decrease in both apoptotic rate and
proliferation in the androgen-sensitive Dunning R3327 PAP
grown in rat (Westin et al, 1995b), and the androgen sensitive
Dunning G grown in mouse (Westin et al, 1997). Furthermore, no
increase in apoptosis was seen after androgen deprivation in
LnCaP xenografts (Gleave et al, 1992). Thus, these experimental
models may each mimic aspects of the behaviour of human
prostate tumours in individual patients after androgen deprivation.
Bcl-2 and bax
Bcl-2 belongs to a family of oncoproteins regulating apoptosis,
and has an anti-apoptotic function. Recent studies have shown
that genetically engineered overexpression of the bcl-2 gene in
androgen-sensitive prostate cancer cells confers resistance to
androgen depletion in vivo (Raffo et al, 1995, Westin et al 1997). It
has been speculated that bcl-2 expression would increase when a
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prostate tumour relapses. Two studies have shown bcl-2
immunoreactivity to be high in relapsed human prostate cancers
(McDonnell et al, 1992; Colombel et al, 1993). However, median
bcl-2 reactivity was significantly increased by androgen with-
drawal in both groups in this series 1 week after therapy.
Moreover, in non-relapsed human prostate cancers investigated at
a mean time of 22 months after castration we observed that bcl-2
immunoreactivity was high (Stattin et al, 1996b). This indicates
that an up-regulation of bcl-2 expression or a selection for bcl-2-
expressing cells is permanently at work after androgen withdrawal
in most human prostate tumours, and does not seem to be restricted
to relapsed androgen-independent tumours. Moreover, recent
studies have shown that bcl-2 can also exhibit antiproliferative
effects (Pietenpol et al, 1994; Vairo et al, 1996). Thus, the down-
regulation ofthe number ofcycling cells seen in both groups in the
present series may be related to the increase in bcl-2.
Another member of the bcl-2 family, the apoptosis-accelerating
bax protein, was also studied. Bax immunoreactivity was wide-
spread in all tumours, in accordance with an earlier study
(Krajewska et al, 1996). Therefore, the balance between bcl-2 and
bax immunoreactivity does not seem to explain the tendency of
cells in prostate tumours to undergo apoptosis. Apparently, other
proteins interacting with bcl-2 such as bcl-x,, bcl-xs, bag and bad
will have to be explored to fully elucidate this issue.
p53
Wild-type p53 is a tumour-suppressor gene regulating both prolif-
eration and apoptosis, but the mutated form is a dominant
oncogene (Greenblatt et al, 1994). The aberrant gene product of
mutated p53 has a long half-life and can consequently be detected
by immunoreactivity (Greenblatt et al, 1994). In the present series,
p53 immunoreactivity was detected in 10% of the tumours before
therapy, in accordance with the rate in most earlier series of
prostate tumours [for a summary ofthe literature see (Stattin et al,
1996a)]. After castration, another three responding tumours were
reactive at low frequency, this may be due to tumourheterogeneity
and sampling of different cell populations or it may be due to an
induction of wild-type p53. p53 immunoreactivity did not appear
to be useful for predicting the outcome ofcastration therapy.
Fas
Fas/APO-l/CD95 is a cell-surface receptor protein known to
trigger apoptosis in a variety of cell types upon specific antibody
binding, for example Fas ligand (Suzuki et al, 1996). In the normal
mouse prostate, castration causes massive apoptosis, followed by
a down-regulation of bcl-2 and induction of Fas expression.
However, in Fas-lacking mice no involution of the prostate was
seen after castration, suggesting a major role for Fas in castration-
induced apoptosis in the prostate (Suzuki et al, 1996). Little is
known about the expression of Fas in human prostate tumours. In
this study, Fas immunoreactivity was present in all tumours, in line
with what has been reported in 10 out of 11 tumour cell lines of
human origin (Owen-Schaub et al, 1994). However, there was no
difference in Fas expression between the responding and non-
responding tumours, in accordance with what was described for
Fas-positive cell lines (Owen-Schaub et al, 1994). This may
suggest that defects in the Fas ligand or other factors downstream
of Fas are crucial regulators ofthe Fas apoptotic pathway in some
non-responding human prostate tumours.
Conclusions
The results ofthis study suggest that some but not all of the short-
term cellular effects of castration therapy in human prostate
tumours are differential according to subsequent clinical response.
Induction ofglandular collapse and cytoplasmic vacuolization and
an increase in apoptotic rate were related to favourable outcome.
Conversely, the decrease in proliferative activity was similar in
responding and non-responding tumours. Immunoreactivity for
bcl-2, p53, bax and Fas was not differential according to response.
This suggests that evaluation of signs of regressive morphology
and apoptotic index on haematoxylin-stained sections in biopsies
obtained before and shortly after castration therapy may be treat-
ment-predictive for castration therapy. However, the results are
based on a relatively small amount oftissue from a limited number
of patients. There was a large range for nearly all the investigated
parameters; this can at least partially be explained by tumour
heterogeneity and the sampling of various tumour subpopulations
with different characteristics at different time points. It is clear that
a larger number of patients has to be studied, and that the number
ofbiopsies obtained at each time point has to be increased to mini-
mize these effects in future studies.
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